

## CMBI Credit Commentary - DEXICN

### DEXICN: Debts funded expansion to slow down in 2H

Dexin reported mixed set of interim results, highlighting robust growth of revenue, improved debts profile, but higher reported debts and further growth of MI. Taking cues from its quality land bank in YRD, Dexin recorded strong contract sales growth with good sell-through and cash collections. The company also increased the attributable ratio of its 1H21 presales and land bank newly acquired. Dexin was active in land investments in 1H21 funded by debts, but we expect it to slow down in capital expenditure to meet the regulatory requirements. **Despite the higher MI reported in 1H and active debt funded expansion, we credit to Dexin's sufficient land bank in high tier cities, increasing attributable ratio, improvement in debt profile, and believe regulatory requirement will curb its land investment in 2H. We maintain our OW on DEXICN, and view DEXICN 22s at 14%-15% are attractive carry play.**

**Strong P&L growth albeit margin compressed.** Dexin reported revenue of RMB13.bn (+69% yoy), EBITDA of RMB2.2bn (+31%) and net income of RMB1.4bn (+3% yoy). GPM normalized to 22% (2020: 25%). Company guided to book RMB20-23bn in 2021FY with GPM stabilized at 22%. NCI as of total profits increased to 54% (1H2020: 48%).

**Robust pre-sales with improved attributable ratio.** Dexin delivered contract sales of RMB43bn (+67% yoy) with higher attributable ratio of 41% (2020: 31%) and consolidated ratio of 52% (2020: 50%). The company has maintained good sell through ratio and cash collection ratio (80% and 85%, respectively) as a result of strong market position in high tier cities in Yangtze River Delta area. We expect the company to achieve full year sales target of RMB80bn.

**Active land replenishment in 1H21 pushed total debts higher, but "3-red-line" metrics remain stable.** With strong contract sales and cash collection, Dexin was proactive in land acquisition and purchased 27 land parcels for attributable saleable GFA of 3.4mm sqm (50% attributable) with RMB13.5bn attributable costs (unpaid premium: RMB6.1bn). Dexin increased M&A as land acquisition channel, taking account of 59% of the GFA acquired and 64% of the attributable land expenditure. We estimated

**Wilson Lu** 路伟同

(852) 3761 8918

wilsonlu@cmbi.com.hk

**Glenn Ko, CFA** 高志和

(852) 3657 6235

glennko@cmbi.com.hk

**Polly Ng** 吴宝玲

(852) 3657 6234

pollyng@cmbi.com.hk

**James Wen** 温展俊

(852) 3757 6291

jameswen@cmbi.com.hk

**CMBI Fixed Income**

fis@cmbi.com.hk

the average land cost to be RMB7.9k per sqm, equivalent to 37% of the ASP in 1H21's presales (RMB21k per sqm). With the sizable unpaid land premium of RMB6.1bn, we expect Dexin to slow down in land investments in 2H21, to meet the regulatory guidance that limits developers' land investment below 40% of pre-sales. As of 1H21, Dexin has unsold land bank of 14mn sqm (attributable ratio of 45%), translating into saleable resources of about RMB294bn, which is sufficient for at least 3 years of developments.

Following the land replenishment activities, Dexin's total debts increased to RMB32.4bn (+37%). We estimate Dexin will maintain similar debts level in 2021E, and fund the unpaid land premium through sales collection in 2H21. "3-red-line" metrics remain stable, as cash/ST debts reported 1.4x (2020: 1.4x), net gearing reported 72% (2020: 75%), and adj. lia-to-ast ratio reported 74% (2020: 74%).

**Good market position in high tier cities helped Dexin's bank borrowings.** Dexin increased bank loans to 63% as of total debts (2020: 56%), thanks to higher development loans incurred by active land acquisition in 1H. As a result, Dexin further eased its reliance on non-bank borrowings to 20% from 28% in 2020. With that, Dexin's average funding costs lowered to 8.1% from 8.9%.

**Dexin's MI further increased to 70%, high among sector peers.** Dexin reported higher MI of 70% as of total equity, from 65% in 2020. The rising MI stems from historically low attributable ratio of Dexin's projects. Despite the fact that more reliance on MI lowers Dexin's financial transparency, we understand that the majority of its JV partners are property developers, instead of financial investors. With the higher attributable ratio of its newly acquired land bank, we expect the MI to decrease gradually.

---

*CMB International Securities Limited*

*Fixed Income Department*

*Tel: 852 3761 8867/ 852 3657 6291*

[fis@cmbi.com.hk](mailto:fis@cmbi.com.hk)

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

### Disclaimer

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap.

**30 Aug 2021**

---

289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.